Compare Cipla with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DR. REDDYS LAB - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DR. REDDYS LAB CIPLA/
DR. REDDYS LAB
 
P/E (TTM) x 36.9 43.5 84.8% View Chart
P/BV x 4.0 5.9 68.8% View Chart
Dividend Yield % 0.4 0.4 99.1%  

Financials

 CIPLA   DR. REDDYS LAB
EQUITY SHARE DATA
    CIPLA
Mar-19
DR. REDDYS LAB
Mar-19
CIPLA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6782,875 23.6%   
Low Rs4841,888 25.6%   
Sales per share (Unadj.) Rs198.2930.2 21.3%  
Earnings per share (Unadj.) Rs18.5117.4 15.8%  
Cash flow per share (Unadj.) Rs35.0185.8 18.8%  
Dividends per share (Unadj.) Rs3.0020.00 15.0%  
Dividend yield (eoy) %0.50.8 61.5%  
Book value per share (Unadj.) Rs186.3844.4 22.1%  
Shares outstanding (eoy) m805.70166.07 485.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.92.6 114.5%   
Avg P/E ratio x31.420.3 154.6%  
P/CF ratio (eoy) x16.612.8 129.5%  
Price / Book Value ratio x3.12.8 110.5%  
Dividend payout %16.217.0 95.1%   
Avg Mkt Cap Rs m468,031395,496 118.3%   
No. of employees `00022.622.0 103.1%   
Total wages/salary Rs m28,56533,562 85.1%   
Avg. sales/employee Rs Th7,053.17,032.8 100.3%   
Avg. wages/employee Rs Th1,261.51,527.9 82.6%   
Avg. net profit/employee Rs Th659.1887.7 74.2%   
INCOME DATA
Net Sales Rs m159,710154,482 103.4%  
Other income Rs m4,7663,375 141.2%   
Total revenues Rs m164,475157,857 104.2%   
Gross profit Rs m30,97331,782 97.5%  
Depreciation Rs m13,26311,348 116.9%   
Interest Rs m1,684889 189.5%   
Profit before tax Rs m20,79122,920 90.7%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6953,858 147.6%   
Profit after tax Rs m14,92419,500 76.5%  
Gross profit margin %19.420.6 94.3%  
Effective tax rate %27.416.8 162.7%   
Net profit margin %9.312.6 74.0%  
BALANCE SHEET DATA
Current assets Rs m124,266111,101 111.8%   
Current liabilities Rs m37,71558,973 64.0%   
Net working cap to sales %54.233.7 160.6%  
Current ratio x3.31.9 174.9%  
Inventory Days Days9179 114.2%  
Debtors Days Days9594 100.7%  
Net fixed assets Rs m105,190101,245 103.9%   
Share capital Rs m1,611830 194.1%   
"Free" reserves Rs m148,511139,406 106.5%   
Net worth Rs m150,123140,236 107.1%   
Long term debt Rs m38,30122,000 174.1%   
Total assets Rs m239,633224,656 106.7%  
Interest coverage x13.326.8 49.8%   
Debt to equity ratio x0.30.2 162.6%  
Sales to assets ratio x0.70.7 96.9%   
Return on assets %6.99.1 76.4%  
Return on equity %9.913.9 71.5%  
Return on capital %11.814.9 79.2%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41088,673 64.7%   
Fx outflow Rs m19,04119,104 99.7%   
Net fx Rs m38,36869,569 55.2%   
CASH FLOW
From Operations Rs m16,91128,704 58.9%  
From Investments Rs m-16,687-7,727 216.0%  
From Financial Activity Rs m-3,487-21,326 16.4%  
Net Cashflow Rs m-3,451-314 1,099.1%  

Share Holding

Indian Promoters % 16.0 25.5 62.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 5.4 225.9%  
FIIs % 23.7 35.3 67.1%  
ADR/GDR % 1.1 18.5 5.9%  
Free float % 26.2 15.3 171.2%  
Shareholders   161,166 75,885 212.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SHASUN PHARMA  STERLING BIOTECH  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  IPCA LABS  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 138 Points Lower; Dow Futures Down by 124 Points(12:30 pm)

Share markets in India are presently trading marginally lower. The BSE Sensex is trading down by 138 points, down 0.3%, at 40,566 levels.

Related Views on News

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Oct 22, 2020 02:44 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS